Biomedical Engineering Reference
In-Depth Information
5. Verstraete M. (2000) Third-generation thrombolytic drugs.
Am. J. Med. 109, 52-58.
6. VanZonnefeldAJ, VermanH, PannekoekH. (1986)Autonomous
functions of structural domains on human tissue-type plasmino-
gen activator. Proc. Natl. Acad. Sci. USA 83, 4670-4674.
7. Lijnen HR, Stump DC, Collen D. (1996) Single-chain uro-
kinase-type plasminogen activator (prourokinase). In: Mess-
erly FH (Ed), Cardiovascular Drug Therapy. 2nd Ed. WB
Saunders, Philadelphia, pp. 1578-1587.
8. Nelles L, Lijnen HR, Collen D, Holmes WE. (1987) Charac-
terization of a fusion protein consisting of amino acids 1 to 263
of tissue-type plasminogen activator and amino acids 144 to
411 of urokinase-type plasminogen activator. J. Biol. Chem.
262, 10855-10862.
9. Urlaub, G, Chasin LA. (1980) Isolation of Chinese hamster cell
mutants deficient in dihydrofolate reductase activity. Proc.
Natl. Acad. Sci. USA 77, 4216-4220.
10. Colucci M, Cavallo LG, Agnelli G, Mele A, Burgi R, Heim J,
et al. (1993) Properties of chimeric (tissue-type/urokinase-
type) plasminogen activators obtained by fusion at the plasmin
cleavage site. Thromb. Haemost. 69, 466-472.
11. Guimaraes AHC, Rijken DC. (2004) Thrombin activable
fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasmino-
gen activator concentration-dependent manner. Thromb.
Haemost. 91, 473-479.
12. Guimaraes AHC, Barrett-Bergshoeff MM, Criscuoli M, Evan-
gelista S, Rijken DC. (2006) Fibrinolytic efficacy of Amedi-
plase, Tenecteplase and scu-PA in different plasma clot lysis
models. Thromb. Haemost. 96, 325-330.
13. Rijken DC, Barrett-Bergshoeff MM, Jie AFH, Criscuoli M,
Sakharov DV. (2004) Clot penetration and fibrin binding of
Amediplase, achimeric plasminogen activator (K2-tu-PA).
Thromb. Haemost. 91, 52-60.
14. Agnelli G, Pascucci C, Colucci M, Nenci GG, Mele A, Burgi
R, et al. (1992) Thrombolytic activity of two chimeric recom-
binant plasminogen activators (FK 2 tu-PA and K 2 tu-PA) in
rabbits. Thromb. Haemost. 68, 331-335.
15. Agnelli G, Pascucci C, Nenci GG, Mele A, Burgi R, Heim J.
(1993) Thrombolytic and haemorrhagic effects of bolus doses
of tissue-type plasminogen activator and a hybrid plasminogen
activator with prolonged plasma half-life (Amediplase: CGP
42935). Thromb. Haemost. 70, 294-300.
16. Report on file at Menarini Ricerche SpA. Evaluation of
fibrinolytic activity in a model of arterial thrombosis induced
by ferric chloride in the rat following single intravenous
administration. June 2001. CERB study n 20010026PGR.
17. Report on file at Menarini Ricerche SpA. Thrombolytic activ-
ity of Amediplase and tenecteplase on FeCl3-induced arterial
thrombosis in the rat. Menarini Ricerche. 2005. Report MRPO-
2005-PHA004.
18. Lucchesi BR, Burgi R, Heim J. (1991) The in vivo thrombo-
lytic activity of CGP 42935, a hybrid plasminogen activator
and fibrinolytic agent. Coron. Artery Dis. 2, 247-258.
19. Report on file at Menarini Ricerche SpA. Pharmacokinetics in
Monkeys of a chimeric plasminogen activator (K 2 tu-PA) link-
ing the kringle2 domain of t-PA to the catalytic domain of scu-
PA. April 1991.
20. Report on file at Menarini Ricerche SpA. Pharmacokinetics of
Amediplase Following Single Intravenous Administration in
Rats. October 2004. Menarini Ricerche Report MR0016.
21. Report on file at Menarini Ricerche SpA. The in vivo fate of the
K 2 TU-PA (Amediplase)
in Rats. January 2004. Leiden/
Amsterdam CDR Report.
22. Report on file at Menarini Ricerche SpA, Study 1K2. Evalua-
tion of the safety, tolerance and pharmacokinetics of single
sequentially rising doses of the plasminogen activator K2tu-PA
in healthy volunteers. February 1995.
23. Vermeer F, Oldroyd K, Pohl J, Giannelli S, Charbonnier B.
(2001) Safety and angiography data of Amediplase, a new
fibrin specific thrombolytic agent, given as a single bolus to
patients with acute myocardial infarction: the 2k2 dose finding
trial. Circulation 104(17, Suppl. 2), abstract 2545.
24. Report on file at Menarini Ricerche SpA Study 2K2. A phase
II, multicentre, open label, dose finding, pilot study of K2tu-PA
in patients with suspected acute myocardial infarction treated
with heparin and aspirin. July 2001.
25. Charbonnier B, Pluta W, De Ferrari G, Ceddia F, Capriati A,
Van de Werf F. (2001) Evaluation of two weight adjusted single
bolus doses of Amediplase to patients with acute myocardial
infarction: the 3k2 trial. Circulation 104(17, Suppl. 2), abstract
2546.
26. Report on file at Menarini Ricerche SpA. Study 3K2. A double
blind, randomised, parallel group study to compare the efficacy
and safety of two doses of Amediplase given as a single i.v.
bolus injection in patients with suspected acute myocardial
infarction treated with heparin and aspirin. June 2003.
27. Report on file at Menarini Ricerche SpA. Menarini Ricerche
Study n 3K2”, Menarini Ricerche Report MR0035. Pharma-
cokinetics of Amediplase in plasma of patients participating in
the clinical trial ”A double blind randomised, parallel group
study to compare the efficacy and the safety of 2 doses of
Amediplase given as a single i.v. bolus injection in patients
with suspected acute myocardial infarction (AMI) treated with
Heparin and Aspirin. May 2003.
28. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalb-
fleisch JM, et al. (1996) For the RAPID II investigators.
Randomized comparison of coronary thrombolysis achieved
with double-bolus reteplase (recombinant plasminogen activa-
tor) and front-loaded, accelerated alteplase (recombinant tissue
plasminogen activator) in patients with acute myocardial
infarction. Circulation 94, 891-898.
29. Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger
MJ, Sequeira RF, et al. (1998) For the thrombolysis in myo-
cardial infarction (TIMI) 10B investigators. TNK-tissue plas-
minogen activator compared with front-loaded alteplase in
acute myocardial infarction results of the TIMI 10B trial.
Circulation 98, 2805-2814.
Search WWH ::




Custom Search